Le Lézard
Classified in: Health, Science and technology

Knipper's New SamplicitySA Is the Next Generation of Sample Management


LAKEWOOD, N.J., August 3, 2021 /PRNewswire-PRWeb/ -- With its many advancements, the user-friendly SamplicitySA creates greater operational efficiencies and provides a simplified and more intuitive user experience, keeping users more informed and compliant than ever before.

One of the most unique features of SamplicitySA is a robust yet, easy-to-use Compliance Scorecard, which collects and reports on a full-range of information in key, compliance-driven areas. Highly configurable, SamplicitySA generates data sets collected on regional, district, and specific sales representative levels. With this enhanced analytical power, users can easily review the timeliness of shipment acknowledgements, signature audit responses, reconciliation items, theft/losses in the field, delayed inventory submissions and much more. The Compliance Scorecard has several different charts available and is a great way to show and track metric trends over time.

"In developing our new SamplicitySA system, Knipper included input from both our clients and internal stakeholders," states Knipper's Chief Commerical Growth Officer, Eric Johnson. "One of our key goals was to create the quickest path to get users to the data they need, which is precisely what we've been able to achieve." Featuring simplified navigation, the SamplicitySA Dashboard provides faster, more complete visibility and transparency across the entire Sample Accountability program, while delivering deeper analysis and evaluation of the overall samples program.

SamplicitySA Sample Management is an integral component of Samplicity, Knipper's fully-integrated sample management platform. As a one-of-a-kind suite of products, services and support, Samplicity satisfies a full-range of sampling program requirements, serving the needs of pharmaceutical manufacturers, practitioners and patients.

The platform helps clients achieve their goals more economically and with fewer resources. Sales personnel can spend their time selling rather than managing their sample orders, or the sample requests of their customers. Marketing Directors benefit from Samplicity's intuitive Dashboard to expand sample programs effectively and cost efficiently. Finally, emerging companies can take advantage of Samplicity's multiple functions to avoid managing multiple suppliers and subsequently reduce costs.

Eric Johnson concludes, "Users will discover that the SamplicitySA graphical presentation of data and its modern user interface (UI) deliver a highly intuitive look and feel that enhances experience and dramatically simplifies navigation."

Knipper is currently scheduling demonstrations of the new SamplicitySA Sample Accountability program. Interested parties are asked to contact Eric Johnson via email at [email protected] or by calling 732-987-7151.

# # #

About Samplicity
Named for its simple approach to sample management, Samplicity revolutionizes sample management for prescription and over-the-counter (OTC) pharmaceutical products with an exclusive suite of technology, services, and support. It is the only completely self-contained, sample management platform available. Samplicity's fully-integrated platform brings to the market a rapid deployment model, coupled with flexible configuration technology to address a full spectrum of sample management needs and requirements.

About J. Knipper and Company, Inc.
For 35 years, J. Knipper and Company, Inc. has been purpose-built on a strong foundation of healthcare service, support, and excellence. It is a leader in the arena of sampling distribution, prescriber validation, sample accountability, web ordering solutions and third-party logistics. The company has locations throughout New Jersey, Indiana, Kenntucky, and Florida. For more information on J. Knipper and Company please visit, http://www.knipper.com.

For additional press information, please contact:
Ilena Della Ventura
Delia Associates
T. 908-534-9044
E. [email protected]

Media Contact

Ilena Della Ventura, Delia Associates, 908-534-9044, [email protected]

 

 

SOURCE J. Knipper and Company, Inc.


These press releases may also interest you

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...

at 03:16
First quarter Net sales reached SEK 9.4 (13.0) million.The operating result totaled SEK -18.4 (-14.4) million.Earnings per share, basic and diluted, were SEK -0.11 (-0.09).Cash flow from operating activities totaled SEK -7.3 (-12.2) million.CEO...

at 03:03
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its platform for medical education, Sectra Education Portal, to four university colleges in Denmark. With the solution, they aim to elevate the educational...

at 03:00
Sentrycs, a leading innovator in adaptive counter-drone solutions, is proud to announce its inclusion in the prestigious UK National Protective Security Authority Catalogue of Security Equipment (NPSA CSE).  ...

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...



News published on and distributed by: